

PATIENT GEP STARTER GUIDE

Know your melanoma.

Receiving a melanoma diagnosis can be scary and overwhelming. With DecisionDx-Melanoma, you can better understand the risk of your melanoma spreading or coming back.

If you think DecisionDx-Melanoma may be right for you, you can use the following resources in the Patient GEP Starter Guide to help facilitate a conversation with your healthcare provider.

1

Patient Resource Guide

2

Patient Discussion Guide

1

Patient Resource Guide

If you or someone you know has been diagnosed with melanoma, you can use the following Patient Resource Guide to help determine if DecisionDx-Melanoma may be right for you.

The Patient Resource Guide provides additional information about:

- What is the DecisionDx-Melanoma test?
- What information do the results provide?
- What do the results mean?
- What is the testing process for DecisionDx-Melanoma?

Patient Resource Guide

Help with understanding your risk after cutaneous melanoma diagnosis



What is melanoma?

Melanoma is one of the three most common types of skin cancer.^{1,2} While some people are at a higher risk than others, anyone can get melanoma.

What is DecisionDx-Melanoma?

DecisionDx-Melanoma is a gene expression profiling (GEP) test that looks at your tumor biology to predict the risk of your melanoma spreading or coming back. The DecisionDx-Melanoma test uses a small sample from the melanoma biopsy that your provider has already taken and it measures the activity of 31 genes that are related to a diverse range of biologic processes.

Measuring the tumor's genetic expression helps to predict how aggressive the tumor will be. This information can give you and your healthcare provider a clearer picture of your prognosis and help you and your care team make personalized management decisions.

The results can help guide:



Sentinel lymph node biopsy (SLNB) procedure decisions



Frequency of follow-up appointments with your healthcare provider



Additional visits with other specialists (referrals)



Other escalations or de-escalations of your management plan

What do the results mean?

The test results provide you and your healthcare professional with information to guide your care, including:

1

Class Result & GEP Score

A risk-stratification class according to your tumor biology.



Class 1A
Lowest risk



Class 1B/2A
Increased risk



Class 2B
Highest risk

2

i31-ROR

Individualized Risk of Recurrence

Personalized risk estimates of your cancer coming back or spreading within the next 5-years

3

i31-SLNB

Individual Risk of Sentinel Lymph Node Positivity

Personalized risk estimate for how likely you are to have a positive sentinel lymph node biopsy

Our testing process

Getting the DecisionDx-Melanoma test is simple. Since the test sample is taken from your original biopsy or surgery, there is no need for another procedure or blood draw. Once completed, the test results are sent directly to your healthcare professional and they will discuss the results and next steps with you.

How much does the test cost?

Castle Biosciences is committed to providing high quality molecular testing to all patients. We do not want financial concerns to be a barrier to patients accessing critical healthcare information.

We will work with all insurance providers, including Medicare, Medicaid, commercial insurers, and Veterans Affairs (VA), to secure payment coverage for our testing.

For those who may need additional assistance with their Castle test, we offer a comprehensive patient assistance program to all patients.

If you have any questions, please contact us by calling 866-788-9007, option 3 or emailing reimbursement@castlebiosciences.com.

The leader in melanoma prognostic testing



1

the only melanoma prognostic test shown to be associated with improved patient survival^{1,9}

Medicare

covered by Medicare and multiple private insurers

150,000+

patients tested*

1 in 2

patients tested had change in management based on their DecisionDx-Melanoma results⁴⁻⁸

10,000+

patients studied in more than 50 publications, including a collaboration with the National Cancer Institute*

For more information, visit:
mymelanoma.com

1. National Cancer Institute. Skin Cancer (Including Melanoma) – Patient Version.
2. Centers for Disease Control and Prevention. Basic Information About Skin Cancer.
3. Bailey et al. *JCO PO*. 2023.
4. Dillon et al. *CMRO*. 2022.
5. Berger et al. *CMRO*. 2016.

6. Dillon et al. *SKIN J Cutan Med*. 2018.
7. Farberg et al. *J Drugs Derm*. 2017.
8. Schuitevoerder et al. *J Drugs Derm*. 2018.
9. Dhillion et al. *Archives of Derm Research*. 2023.

*As of December 2023

2

Patient Discussion Guide

After reviewing the Patient Resource Guide, if you think DecisionDx-Melanoma may be right for you, print the following Patient Discussion Guide and bring it to your next appointment with your healthcare professional.

The Patient Discussion Guide includes questions to help facilitate a conversation with your healthcare professional about if DecisionDx-Melanoma may be right for you.



Discussion Guide

This discussion guide, along with our Patient Resource Guide, can be used to assist you in a conversation with your healthcare professional to help determine if DecisionDx®-Melanoma is right for you.

DecisionDx-Melanoma is a genomic test that looks at your tumor's biology to better understand your personal risk of metastasis or recurrence within 5 years and likelihood of sentinel lymph node positivity. Individualized test results can help you and your healthcare professional make decisions about:



Follow-up appointments with your healthcare provider



Additional visits with other specialists (referrals)



Sentinel lymph node biopsy (SLNB) procedure



Other escalations or de-escalations of your management plan

About Melanoma

- Melanoma occurs when the skin cells that give your skin color (melanocytes) are damaged and begin to grow out of control.
- Melanoma is one of the three most common types of skin cancer. While some people are at a higher risk than others, anyone can get melanoma.
- When melanoma is diagnosed, it is classified into different stages based on its pathology features, such as how deep the tumor is, if ulceration is present, or if melanoma cells have spread to the lymph node basin.
- Melanoma can be staged as: In situ, Stage I, Stage II, Stage III, and Stage IV.

About DecisionDx-Melanoma

- Patients with Stage I-III cutaneous melanoma are eligible for the test.
- Castle Biosciences integrates clinical and pathological features (such as Breslow depth, ulceration, and mitosis) with your DecisionDx-Melanoma test result to help provide you with a more personalized risk assessment.

Questions to ask your care team

How can DecisionDx-Melanoma be beneficial for me?

What do the test results mean?

How could this test be used to inform my management decisions?

Additional notes:

Castle Biosciences is committed to providing high-quality molecular testing to all patients. We do not want financial concerns to be a barrier to you accessing critical healthcare information.

We will work with all insurance providers, including Medicare, Medicaid, commercial insurers, and Veterans Affairs (VA), to secure payment coverage for our testing.

For those who may need additional assistance with their Castle test, we offer a comprehensive patient assistance program

For more information visit: [MyMelanoma.com](https://www.MyMelanoma.com) or call 866-788-9007 option 1

DecisionDx

► Melanoma

If you think that DecisionDx-Melanoma may be right for you, your healthcare provider can download the Test Requisition Form at:

[**castlebiosciences.com/order**](https://castlebiosciences.com/order)